NON-ISOTOPIC IMMUNOASSAY MARKETS IN EUROPE:
REAGENTS, INSTRUMENTATION AND SYSTEMS
FROST & SULLIVAN INC.
C O N T E N T S
Page
EXECUTIVE SUMMARY ES.1
CHAPTER 1: INTRODUCTION, SCOPE AND METHODOLOGY 1.1
1.1 Introduction 1.1
1.2 Objectives and Scope of this Report 1.4
1.3 Definitions - Product Groups, Application Groups
and End-users Covered in the Report 1.6
1.4 Outline of the Report 1.8
1.5 Information Sources and Methodology 1.11
1.6 Currency Exchange Rates 1.13
CHAPTER 2: IMMUNOASSAY TECHNOLOGY AND PRODUCTS 2.1
2.1 Introduction 2.1
2.2 Technological Basis of Immunoassays 2.2
2.2.1 Introduction 2.2
2.2.2 Separation Methods and Formats 2.7
2.2.3 Labels, End Signals and Readers 2.8
2.2.4 Types of Instrumentation 2.15
2.2.4.1 Introduction 2.15
2.2.4.2 Nephelometers 2.15
2.2.4.3 Spectrophotometers 2.16
2.2.4.4 Fluorimeters 2.16
2.2.4.5 Luminometers 2.17
2.2.5 The Automation Challenge 2.17
2.2.6 Immunoassay Systems 2.22
2.3 Non-isotopic Immunoassay Products 2.26
2.3.1 Nephelometric Immunoassay Products 2.26
2.3.1.1 Reagents 2.26
2.3.1.2 Instruments 2.28
2.3.1.3 Semi- and Fully Automated Systems 2.29
2.3.2 Colourimetric Immunoassay Products 2.33
2.3.2.1 Reagents 2.33
2.3.2.2 Instrumentation 2.37
2.3.3 Fluorimetric Immunoassay Products 2.40
2.3.3.1 Introduction 2.40
2.3.3.2 Reagents 2.43
2.3.3.3 Instrumentation 2.44
2.3.4 Chemiluminometric Assays 2.47
2.3.4.1 Introduction 2.47
2.3.4.2 Reagents 2.47
2.3.4.3 Instruments 2.49
2.3.5 Component Systems 2.51
2.3.6 Proprietary Modular Systems 2.54
2.3.7 Fully Automated Immunoassay Systems 2.54
2.3.8 Automated Systems for Homogeneous
Immunoassay 2.76
2.4 Definitions of the Product Groups Used for the
Quantitative Market Analyses 2.81
CHAPTER 3: APPLICATIONS AND END-USERS OF NON-ISOTOPIC
IMMUNOASSAY PRODUCTS, AND MARKET
SEGMENTATION 3.1
3.1 Applications 3.1
3.1.1 Thyroid 3.1
3.1.2 Reproductive Endocrinology 3.2
3.1.2.1 LHRH, LH, FSH 3.2
3.1.2.2 Human Prolactin 3.4
3.1.3 Other Endocrinology 3.4
3.1.3.1 ACTH and Cortisol 3.4
3.1.3.2 Renin - Angiotensin - Aldosterone 3.5
3.1.3.3 Growth Hormone 3.5
3.1.3.4 Parathormone 3.5
3.1.4 Haematology 3.6
3.1.5 Allergy 3.6
3.1.6 Cancer 3.7
3.1.7 Therapeutic Drug Monitoring/Drugs of Abuse 3.8
3.1.8 Plasma Proteins 3.9
3.1.9 Serology 3.10
3.1.10 Hepatitis 3.11
3.1.10.1 Hepatitis A 3.11
3.1.10.2 Hepatitis B 3.11
3.1.10.3 Hepatitis C (Non-A Non-B) 3.12
3.1.10.4 Delta Hepatitis 3.12
3.1.10.5 Hepatitis E 3.12
3.1.11 HIV 3.13
3.2 End-users of Non-isotopic Immunoassay Products
& Market Segmentation 3.14
3.2.1 Hospital Laboratories 3.14
3.2.2 Private and Commercial Laboratories 3.15
3.2.3 Blood Transfusion Centres 3.16
3.2.4 Public Health/Hygiene Institutes 3.17
3.2.5 Group Practice Laboratories 3.17
3.2.6 Market Segmentation 3.18
3.2.6.1 Factors to be Considered 3.18
3.2.6.2 Market Segmentation for the Markets
under Review 3.21
CHAPTER 4: EUROPEAN ANALYSIS AND FORECASTS 4.1
4.1 Political and Socio-economic Structure 4.1
4.1.1 European Overview - The EC, EFTA and
Comecon Trading Blocks 4.1
4.1.2 Population and Demographic Trends 4.3
4.1.3 GDP and Healthcare Expenditure 4.5
4.2 Healthcare Systems in Europe 4.8
4.3 Regulatory Controls 4.11
4.3.1 France 4.11
4.3.2 Germany 4.13
4.3.3 Italy 4.14
4.3.4 UK 4.14
4.3.5 Other Countries in Europe 4.15
4.4 EEC Market Harmonisation in 1992 4.16
4.4.1 General 4.16
4.4.2 Patents and Trademarks 4.19
4.4.3 Diagnostics Industry Implications 4.20
4.4.3.1 General 4.20
4.4.3.2 Pricing Policy 4.20
4.4.3.3 Speed of New Product Adoption 4.20
4.4.3.4 Effects of 1992 on End-customers 4.21
4.4.3.5 Competitive Position 4.21
4.5 Immunoassay Reagents, Instruments and Systems
Markets in Europe 4.23
4.5.1 European Overview 4.23
4.5.2 European Market Size and Product Group
Breakdown 4.26
4.5.3 European Market: Trends in Non-isotopic
Reagents and Instrumentation Product Groups
and Market Projections 1989-1995 4.32
4.5.4 National Markets Overview and Projections 4.40
4.5.5 Applications Group Overview and Projections 4.47
4.5.6 End-user Overview 4.55
4.5.7 The Competitive Situation in the European
Market 4.61
CHAPTER 5: IMMUNOASSAY REAGENTS,INSTRUMENTS AND SYSTEMS:
EUROPEAN NATIONAL MARKETS ANALYSIS 5.1
5.1 France 5.1
5.1.1 Introduction 5.1
5.1.2 The French Healthcare System 5.1
5.1.3 The French Hospital System 5.5
5.1.3.1 Public Hospitals 5.5
5.1.3.2 Private Hospitals 5.9
5.1.4 Hospital Laboratory Sites 5.9
5.1.5 Private Laboratories in France 5.10
5.1.6 Immunoassays in French Laboratories 5.14
5.1.7 French Non-isotopic Immunoassay Reagents,
Instruments and Systems Markets 5.18
5.2 Germany 5.34
5.2.1 Introduction 5.34
5.2.2 Healthcare in the Western L„nder 5.35
5.2.2.1 Introduction 5.35
5.2.2.2 The Hospital System 5.38
5.2.2.3 Ambulatory Care 5.40
5.2.2.4 Hospital Laboratories in the Western
L„nder 5.43
5.2.2.5 Private Laboratories in the Western
L„nder 5.43
5.2.2.6 Immunoassay in the Western L„nder 5.46
5.2.3 The Eastern Region 5.47
5.2.3.1 Introduction 5.47
5.2.3.2 Hospitals 5.48
5.2.3.3 Ambulatory Care 5.50
5.2.3.4 Laboratories in the Eastern L„nder 5.50
5.2.4 Unification of German Healthcare 5.52
5.2.5 German Non-isotopic Immunoassay Reagents,
Instruments and Systems Markets 5.53
5.3 Italy 5.69
5.3.1 Introduction 5.69
5.3.2 The Italian Healthcare System 5.69
5.3.3 The Italian Hospital System 5.74
5.3.3.1 Italian Public Hospitals 5.74
5.3.3.2 Italian Private Hospitals 5.75
5.3.3.3 Hospital Size Distribution 5.78
5.3.4 Hospital Laboratory Sites 5.78
5.3.5 Poliambulatorios and USL Laboratories 5.80
5.3.6 Private Laboratories in Italy 5.80
5.3.7 The Italian Non-isotopic Immunoassay
Reagents, Instruments and Systems Market 5.81
5.3.8 Competition in the Italian Market 5.96
5.4 United Kingdom 5.100
5.4.1 Introduction 5.100
5.4.2 The UK Hospital System 5.104
5.4.2.1 UK Public Hospitals 5.104
5.4.2.2 UK Private Hospitals 5.105
5.4.2.3 Ambulatory Medicine in the UK 5.109
5.4.3 The UK Laboratory System 5.110
5.4.4 Immunoassay in UK Laboratories 5.112
5.4.5 The Non-isotopic Reagents, Instrumentation
and Systems Markets in the UK 5.114
5.5 Spain 5.129
5.5.1 Introduction 5.129
5.5.2 The Spanish Healthcare System 5.131
5.5.3 Spanish Hospitals 5.132
5.5.4 Ambulatory Care in Spain 5.139
5.5.5 The Spanish Clinical Laboratory System 5.140
5.5.6 The Non-isotopic Immunoassay Reagents,
Instrumentation and Systems Market in Spain 5.142
5.6 Other National Markets in the Rest of Europe 5.158
5.6.1 Belgium 5.158
5.6.1.1 Introduction 5.158
5.6.1.2 The Belgian Healthcare System 5.158
5.6.1.3 Hospitals in Belgium 5.160
5.6.1.4 Ambulatory Care in Belgium 5.163
5.6.1.5 The Belgian Laboratory System 5.163
5.6.2 The Netherlands 5.166
5.6.2.1 Introduction 5.166
5.6.2.2 Healthcare in the Netherlands 5.167
5.6.2.3 The Hospital System in the Netherlands 5.170
5.6.2.4 Ambulatory Care in the Netherlands 5.170
5.6.2.5 The Laboratory System in the
Netherlands 5.172
5.6.3. Scandinavia 5.172
5.6.3.1 Introduction 5.172
5.6.3.2 Denmark 5.174
5.6.3.3 Sweden 5.177
5.6.3.4 Norway 5.178
5.6.3.5 Finland 5.178
5.6.4 Austria and Switzerland 5.179
5.6.4.1 Introduction 5.179
5.6.4.2 Austria 5.179
5.6.4.3 Switzerland 5.182
5.6.5 Ireland, Greece and Portugal 5.184
5.6.6 Non-isotopic Immunoassay reagents,
Instruments and Systems Market in the
Rest of Europe 5.187
CHAPTER 6: SUPPLIER PROFILES 6.1
6.1 Abbott Laboratories, Inc 6.1
6.2 Amerlite Diagnostics 6.4
6.3 Baxter International 6.6
6.4 Beckman Instruments Inc 6.9
6.5 Behringwerke 6.11
6.6 Biomerieux 6.12
6.7 Boehringer Mannheim 6.14
6.8 Diagnostics Pasteur 6.16
6.9 Organon Teknika 6.18
6.10 Pharmacia 6.19
6.11 Roche 6.22
6.12 Ares-Serono Group 6.24
6.13 Sorin Biomedica 6.26
6.14 Syva Corporation 6.27
6.15 Wellcome Diagnostics 6.28
CHAPTER 7: TRENDS, OPPORTUNITIES AND STRATEGIES 7.1
APPENDIX I: LIST OF SUPPLIERS' ADDRESSES A.1
FIGURES AND TABLES
Page
EXECUTIVE SUMMARY
Fig ES1 Non-isotopic Immunoassay Reagents.
European Market, by Country (1989) ES.3
Table ES2 Europe: Installed Base of NIA instruments/
Systems (mid 1990) by National Market ES.5
Fig ES3 Non-isotopic Immunoassay Reagents.
European Market, by Application (1989) ES.6
Fig ES4 Non-isotopic Immunoassay Reagents Market.
European Market, by End-user Segment for
the Top Five Countries in 1989 ES.8
Fig ES5 Non-isotopic Immunoassay Reagents Market
in Europe. Breakdown by Instrument/
Systems Type (1989) ES.9
Fig ES6 Non-isotopic Immunoassay Reagents Market.
European Market, by Country, 1989 and 1995. ES.11
Table ES7 Europe: NIA Reagents Market Projections by
National Market (1989-95) ES.12
Table ES8 Europe: NIA Reagents Market Projections by
Application Group (1989-1995) ES.13
Table ES9 Europe: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) ES.16
Table ES10 Europe: NIA Instrumentation/Systems
Projections. Installed Base (1989-1995) ES.17
Fig ES11 Fully Automated Systems. Availability of
Key Analytes 1990-95 ES.18
Table ES12 Europe: NIA Reagents Market Projections by
Type of Instrumentation Systems 1989-1995) ES.19
Fig ES13 Non-isotopic Immunoassay Reagents Market
in Europe. Projections by Instrument/
System Type ES.20
Table ES14 Europe: NIA Reagents Market (1989). Share
by Supplier ES.21
CHAPTER 1: INTRODUCTION, SCOPE AND METHODOLOGY
Table 1.1 Currency Exchange Rates 1.14
CHAPTER 2: IMMUNOASSAY TECHNOLOGY AND PRODUCTS
Table 2.1 Common Combinations of Labels and Instruments
used in Commercial Non-isotopic Immunoassays 2.14
Table 2.2 Nephelometric Instruments and Systems 2.30
Table 2.3 Test Menus of Beckman and Behring Nephelo-
metric Immunoassay Systems 2.32
Table 2.4 Colourimetric Immunoassay Reagents 2.36
Table 2.5 Colourimetric Immunoassay Instrumentation 2.41
Table 2.6 Fluorimetric Immunoassays 2.46
Table 2.7 Chemiluminometric Immunoassays 2.50
Table 2.8 Fully Automated Immunoassay Systems:
Late 1990 2.56
Table 2.9 Fully Automated Immunoassay Systems 2.58
Fig 2.10 Abbott: IMX 2.59
Fig 2.11 Baxter-Dade: Stratus II 2.60
Fig 2.12 Becton Dickinson: Affinity 2.61
Fig 2.13 Biomerieux: Vidas 2.62
Fig 2.14 Biotrol: S7000 2.63
Fig 2.15 Boehringer-Mannheim: ES600 2.64
Fig 2.16 Boehringer-Mannheim: ES300 2.65
Fig 2.17 Ciba Corning: ACS-180 2.66
Fig 2.18 Cis Bio International: Cis Pack 4200 2.67
Fig 2.19 Mitsui: Quatrus 2.68
Fig 2.20 Olympus: PK310 2.69
Fig 2.21 Polaroid-Behring: Opus 2.70
Fig 2.22 Serono: SRI 2.71
Fig 2.23 Technicon: Immuno-I 2.72
Fig 2.24 Tosoh (Eurogenetics): AIA-600 2.73
Fig 2.25 Tosoh (Eurogenetics): AIA-1200 2.74
Table 2.26 44 Key Non-isotopic Immunoassay Analytes 2.77
Fig 2.27 Fully Automated systems. Availability of
Key Analytes 1990-95 2.78
CHAPTER 3: APPLICATIONS AND END-USERS OF NON-ISOTOPIC
IMMUNOASSAY PRODUCTS, AND MARKET SEGMENTATION
Fig 3.1 Strategies for Thyroid Testing 3.3
Table 3.2 Market Segmentation Factors for End-users
in the European Market 3.23
CHAPTER 4: EUROPEAN MARKET ANALYSIS AND FORECASTS
Table 4.1 Population, Economic & Healthcare Indicators
- Comparative Data for European Countries
Covered in this Report 4.4
Table 4.2 Population and GDP Statistics for Eastern
European Countries (1988) 4.6
Table 4.3 Summary of European Immunodiagnostic
Regulations 4.12
Table 4.4 Europe: Numbers of NIA Instruments/
Systems in Service by Type (mid 1990) and
1989 Placements by Type 4.28
Table 4.5 Europe: The Market for NIA Reagents by Type
of Instrumentation/System (1989) 4.30
Table 4.6 Europe: Non-isotopic Immunoassay Reagents
Market Projections 1989-1995 4.33
Table 4.7 Europe: NIA Instrumentation/Systems
Projections. Installed Base (1989-1995) 4.35
Table 4.8 Europe: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 4.36
Table 4.9 Europe: NIA Reagents Market Projections by
Type of Instrumentation/Systems (1989-1995) 4.37
Table 4.10 Europe: The Market for NIA Reagents by Type
of Instrumentation/System. Comparison of
the Market in 1995 with that of 1989 4.41
Table 4.11 Europe: The Market for NIA Reagents by
National Market (1989) 4.43
Table 4.12 Europe: Installed Base of NIA Instrumentation/
Systems (mid 1990) by National Market 4.44
Table 4.13 Europe: The Market for NIA Reagents ($m) by
Type of Instrumentation/System (1989) by
National Market 4.45
Table 4.14 Main Contributors to Growth in the Non-
isotopic Immunoassay Reagents Markets in
Europe 4.48
Table 4.15 Europe: NIA Reagents Market Projections by
National Market (1989-95) 4.49
Table 4.16 Europe: The Market for NIA Reagents by
Application Group (1989) 4.50
Table 4.17 Europe: NIA Reagents Market Projections by
Application Group (1989-1995) 4.54
Table 4.18 Europe: The Market for NIA Reagents by
End-user Segment (1989) for the Top 5
National Markets 4.56
Table 4.19 Europe: NIA Reagents Market (1989). Share
by Supplier 4.62
Table 4.20 Europe: Numbers of NIA Instruments/
Systems in Service in Mid 1990, and Share
by Manufacturer. 4.63
CHAPTER 5: NATIONAL MARKETS IN EUROPE
Table 5.1 Demographic and Economic Indicators -
France 5.2
Table 5.2 Healthcare Indicators - France 5.3
Table 5.3 French Public Hospitals: Distribution by
Type and Bed Size Category (1989) 5.6
Table 5.4 Number of French Public Hospitals by Type
and by Total Bed Capacity (1988) 5.6
Table 5.5 French Public Short Stay Hospitals:
Distribution by Bed Size Capacity.
Number and Percentage of Short Stay Beds 5.7
Table 5.6 Type and Size Distribution of French
Private Hospitals (1988) 5.7
Table 5.7 Clinical Laboratories in France 5.11
Table 5.8 Private Laboratories in France:
Distribution of Reimbursement Revenues 5.12
Table 5.9 Approval of Immunoassays for
Reimbursement in France (1986-1990) 5.15
Table 5.10 France: The Market for NIA Reagents by
Application Group 5.19
Table 5.11 France: The Market for NIA Reagents by
End-user Segment (1989) 5.21
Table 5.12 France: Numbers of NIA Instruments/
Systems in Service by Type (mid 1990)
and 1989 Placements by Type 5.22
Table 5.13 France: The Market for NIA Reagents by
Type of Instrumentation/System (1989) 5.23
Table 5.14 France: NIA Reagents Market Projections by
Application Group (1989-1995) 5.25
Table 5.15 France: NIA Instrumentation/Systems
Projections. Numbers in Service by Type
(1989-1995) 5.27
Table 5.16 France: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.28
Table 5.17 France: The Market for NIA Reagents by Type
of Instrumentation/System. Comparison of
the Market in 1995 with that of 1989 5.29
Table 5.18 France: NIA Reagents Market Projections by
Type of Instrumentation/System (1989-1995) 5.30
Table 5.19 France: NIA Reagents Market (1989). Share
by Supplier 5.32
Table 5.20 Demographic and Economic Indicators -
Germany 5.36
Table 5.21 Healthcare Indicators - Germany 5.37
Table 5.22 German Hospitals: Distribution by Type and
Bed Size Category (1987). All Hospitals 5.39
Table 5.23 German Hospitals: Distribution by Type and
Bed Size Category (1987). Acute Hospitals 5.41
Table 5.24 Numbers and Type of German Hospitals in the
Western L„nder, and Total Bed Capacity (1987) 5.41
Table 5.25 Clinical Laboratories in Germany (Western
L„nder) 5.44
Table 5.26 Numbers and Type of German Hospitals in the
Eastern L„nder, and Total Bed Capacity (1988) 5.49
Table 5.27 Ambulatory Care Facilities in the Eastern
Region of Germany 5.51
Table 5.28 Germany: The Market for NIA Reagents by
Application Group (1989) 5.54
Table 5.29 Germany: The Market for NIA Reagents by
End-user Segment (1989) 5.56
Table 5.30 Germany: Numbers of NIA Instruments/Systems
in Service by Type (mid 1990) and 1989
Placements by Type 5.57
Table 5.31 Germany: The Market for NIA Reagents by Type
of Instrumentation/System (1989) 5.58
Table 5.32 Germany: NIA Reagents Market Projections by
Application Group (1989-1995) 5.60
Table 5.33 Germany: NIA Instrumentation/Systems
Projections. Numbers in Service by Type
(1989-1995) 5.63
Table 5.34 Germany: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.64
Table 5.35 Germany: Market Projections by Type of
Instrumentation/System (1989-1995) 5.65
Table 5.36 Germany The Market for NIA Reagents by Type
of Instrumentation/System. Comparison of
the Market in 1995 with that of 1989 5.66
Table 5.37 Germany: NIA Reagents Market (1989). Share
by Supplier 5.68
Table 5.38 Demographic and Economic Indicators - Italy 5.70
Table 5.39 Healthcare Indicators: Italy 5.72
Table 5.40 Number and Type of Italian Public Hospitals 5.76
Table 5.41 Number and Type of Italian Public Hospitals
and Distribution of Bed Capacity 5.76
Table 5.42 Number, Type and Bed Capacity of Italian
Private Hospitals 5.77
Table 5.43 Italian General Hospitals: Distribution by
Bed Size Category and Bed Capacity 5.79
Table 5.44 Clinical Laboratories in Italy 5.82
Table 5.45 Italy: The Market for NIA Reagents by
Application Group (1989) 5.83
Table 5.46 Italy: The Market for NIA Reagents by
End-User Segment (1989) 5.86
Table 5.47 Italy: Numbers of NIA Instruments/Systems
in Service by Type (mid 1990) and 1989
Placements by Type 5.87
Table 5.48 Italy: The Market for NIA Reagents by Type
of Instrumentation/System (1989) 5.88
Table 5.49 Italy: NIA Reagents Market Projections by
Application Group (1989-1995) 5.90
Table 5.50 Italy: NIA Instrumentation/Systems
Projections. Numbers in Service (1989-1995) 5.92
Table 5.51 Italy: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.93
Table 5.52 Italy: Market Projections by Type of
Instrumentation System (1989-1995) 5.94
Table 5.53 Italy: The Market for NIA Reagents by Type
of Instrumentation/System. Comparison of
the Market in 1995 with that of 1989 5.95
Table 5.54 Italy: NIA Reagents Market (1989). Share
by Supplier 5.97
Table 5.55 Demographic & Economic Indicators for
the UK 5.101
Table 5.56 Healthcare Indicators: UK 5.102
Table 5.57 Public Hospitals in the UK: Total Numbers,
Bed Capacity and Breakdown by Bed Size
Category 5.106
Table 5.58 Public Hospitals in the UK - Unofficial
Statistics. Breakdown of Acute and General
Hospitals by Bed Size Category for Hospitals
with 100 or More Beds 5.107
Table 5.59 Number, Type and Bed Capacity of Private
Acute Hospitals in the UK 5.108
Table 5.60 Clinical Laboratories in the UK 5.113
Table 5.61 UK: The Market for NIA Reagents by
Application Group (1989) 5.116
Table 5.62 UK: The Market for NIA Reagents by
End-User Segment (1989) 5.117
Table 5.63 UK: Numbers of NIA Instruments/Systems in
Service by Type (mid 1990) and 1989
Placements by Type 5.119
Table 5.64 UK: The Market for NIA Reagents by Type
of Instrumentation/System (1989) 5.120
Table 5.65 UK: NIA Reagents Market Projections by
Application Group (1989-1995) 5.121
Table 5.66 UK: NIA Instrumentation/Systems
Projections. Numbers in Service by Type
(1989-1995) 5.123
Table 5.67 UK: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.124
Table 5.68 UK: Market Projections by Type of
Instrumentation System (1989-1995) 5.125
Table 5.69 UK: The Market for NIA Reagents by Type of
Instrumentation/System. Comparison of the
Market in 1995 with that of 1989 5.126
Table 5.70 UK: NIA Reagents Market (1989). Share by
Supplier 5.127
Table 5.71 Demographic and Economic Indicators - Spain 5.130
Table 5.72 Healthcare Indicators: Spain 5.133
Table 5.73 Number, Type and Bed Capacity of Spanish
Hospitals (1987). Latest Official Statistics 5.134
Table 5.74 Spanish Hospitals (1987): Breakdown
by Function and Bed Capacity. Latest
Official Statistics 5.136
Table 5.75 Breakdown by Bed Size Category and Function
for Spanish Hospitals (1987) 5.137
Table 5.76 Breakdown by Bed Size Category and
Administration of Spanish Hospitals (1987).
Latest Official Statistics 5.138
Table 5.77 Clinical Laboratories in Spain 5.141
Table 5.78 Spain: The Market for NIA Reagents by
Application Group (1989) 5.143
Table 5.79 Spain: The Market for NIA Reagents by
End-User Segment (1989) 5.144
Table 5.80 Spain: Numbers of NIA Instruments/Systems
in Service by Type (mid 1990) and 1989
Placements by Type 5.146
Table 5.81 Spain: The Market for NIA Reagents by Type
of Instrumentation/System (1989) 5.147
Table 5.82 Spain: NIA Reagents Market Projections by
Application Group (1989-1995) 5.149
Table 5.83 Spain: The Market for NIA Reagents by Type
of Instrumentation/System. Comparison of
the Market in 1995 with that of 1989 5.151
Table 5.84 Spain: NIA Instrumentation/Systems
Projections. Numbers in Service by Type
(1989-1995) 5.152
Table 5.85 Spain: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.153
Table 5.86 Spain: Market Projections by Type of
Instrumentation System (1989-1995) 5.154
Table 5.87 Spain: NIA Reagents Market (1989). Share
by Supplier 5.156
Table 5.88 Demographic and Economic Indicators:
Belgium 5.159
Table 5.89 Healthcare Indicators: Belgium 5.161
Table 5.90 Number and Type of Belgian Hospitals 5.162
Table 5.91 Belgian Hospitals: Breakdown by Type and
Bed Size Category 5.162
Table 5.92 Clinical Laboratories in Belgium - 1987 5.165
Table 5.93 Demographic and Economic Indicators: The
Netherlands 5.168
Table 5.94 Healthcare Indicators: The Netherlands 5.169
Table 5.95 Hospitals in The Netherlands: Breakdown by
Function (1988) 5.171
Table 5.96 General Hospitals in The Netherlands:
Breakdown by Bed Size 5.171
Table 5.97 Clinical Laboratories in The Netherlands 5.173
Table 5.98 Population and Demographic Indicators for
Scandinavia 5.175
Table 5.99 Healthcare Indicators for Scandinavia (1988) 5.176
Table 5.100 Population and Demographic Indicators:
Austria & Switzerland 5.180
Table 5.101 Healthcare Indicators: Austria & Switzerland
(1987) 5.180
Table 5.102 Demographic, Economic and Healthcare
Indicators: Ireland, Greece & Portugal 5.185
Table 5.103 Non-isotopic Immunoassay Reagents Markets in
the Rest of Europe. Breakdown by National
Markets. 5.188
Table 5.104 Other Countries: NIA Reagents Market Project
-ions by Application Group (1989-1995) 5.190
Table 5.105 Other Countries: NIA Instrumentation/Systems
Projections. Numbers in Service by Type
(1989-1995) 5.192
Table 5.106 Other Countries: NIA Instrumentation/Systems
Projections. Placements by Type (1989-1995) 5.194
Table 5.107 Rest of Europe: The Market for NIA Reagents
by Type of Instrumentation/System.
Comparison of the Market in 1995 with that
of 1989 5.195
Table 5.108 Other Countries: Market Projections by Type
of Instrumentation System (1989-1995) 5.196
|
